(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) fell by a staggering 32.82% in 30 days from $9.75 to $6.55 at 11:13 EST on Monday, after five consecutive sessions in a row of losses. NASDAQ is jumping 1.03% to $10,979.98, after four sequential sessions in a row of losses.
TherapeuticsMD’s last close was $6.22, 84.83% under its 52-week high of $41.00.
TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17ss -estradiol, and progesterone to treat moderate-to–severe vasomotor conditions. TX-015HR is a transdermal progesterone cream. TX-016HR is an estradiol-progesterone cream. TX-048HR is a transdermal patch cream. TX-047HR and TX-048HR are candidates for transdermal patches. TX-049HR is an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins, under the vitaTrue and vitaMedMD brands. It sells prescription drugs and prenatal vitamins to retail pharmacie distributors as well wholesale distributors. TherapeuticsMD, Inc., was established in Boca Raton, Florida in 2008.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of -0.67.
Today’s last reported volume for TherapeuticsMD is 18751 which is 96.78% below its average volume of 583790.
TherapeuticsMD’s sales growth is 8.6% for the current quarter and 3.6% for the next. The company’s growth estimates for the current quarter and the next is 44.7% and 89.6%, respectively.
Year-on-year quarterly revenue growth declined by 2.7%, now sitting on 86.42M for the twelve trailing months.
TherapeuticsMD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.15%, a negative 0.93%, and a positive 6.11%, respectively.
TherapeuticsMD’s highest amplitude of average volatility was 6.83% (last week), 5.02% (last month), and 6.11% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
TherapeuticsMD’s stock is considered to be overbought (>=80).
TherapeuticsMD’s Stock Yearly Top and Bottom Value
TherapeuticsMD’s stock is valued at $6.55 at 11:14 EST, way under its 52-week high of $41.00 and way higher than its 52-week low of $1.99.
TherapeuticsMD’s Moving Average
TherapeuticsMD’s value is way under its 50-day moving average of $8.39 and way below its 200-day moving average of $12.88.
More news about TherapeuticsMD (TXMD).